Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
WHO, (1982),
[2.]
G.M. Marais, K.K. Larson.
Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy.
Ann Intern Med, 112 (1990), pp. 228-232
[3.]
Redacción de La Vanguardia. Sanitat detecta 31 pacientes catalanes afectados por Lipobay. La Vanguardia, 1 de septiembre de 2001
[4.]
Ministerio de Sanidad y Consumo, Sociedad Española de Cardiología y Sociedad Española de Arteriosclerosis. Control de la colesterolemia en España, 2000. Instrumento para la prevención cardiovascular.
Clin Invest Arterioscl, 12 (2000), pp. 122-125
[5.]
D. Wood, G. De Backer, O. Faergerman, I. Graham, G. Mancia, K. Pyorala.
Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.
Eur Heart J, 19 (1998), pp. 1434-1503
[6.]
P.W.F. Wilson, R.B. D’Agostino, D. Levy, A.M. Belanger, H.M. Silvershatz, W.B. Kannel.
Prediction of coronary heart disease using risk factor categories.
Circulation, 97 (1998), pp. 1837-1847
[7.]
National Cholesterol Education Program. Second report of the expert committee on detection, evaluation, and treatment of high blood cholesterol in adults.
Circulation, 89 (1994), pp. 1333-1345
[8.]
National Cholesterol Education Program. Third report of the expert committee on detection, evaluation, and treatment of high blood cholesterol in adults. www.nhbi.nih.gov/guidelines/cholesterol/stp3xsum.pdf
[9.]
The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol levels in adults.
Arch Intern Med, 148 (1988), pp. 36-39
[10.]
P. Plans-Rubió.
Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease.
PharmacoEconomics, 13 (1998), pp. 623-643
[11.]
P. Plans-Rubió.
Cost-effectiveness of cardiovascular prevention programmes in Spain.
Int J Tech Assess Health Care, 14 (1998), pp. 320-330
[12.]
P. Plans Rubió, J. Rovira Forns.
Estudio coste-efectividad de los tratamientos farmacológicos hipolipemiantes.
Med Clín (Barc), 105 (1995), pp. 327-333
[13.]
S.A. Grover, M. Abrahamowicz, L. Josep, C. Brewer, L. Canpol, S. Suissa.
The benefits of treating hyperlipidemia to prevent coronary heart disease: estimating changes in life expectancy and morbidity.
JAMA, 267 (1992), pp. 816-822
[14.]
Acadèmia de Ciències Mèdiques, (2001),
[15.]
M.F. Drummond, B. O’Brien, G.L. Stoddart, G.W. Torrance.
Oxford University Press, (1997),
[16.]
W.B. Kannel, T. Gordon.
The Framingham Study: an epidemiological investigation of cardiovascular disease. Department of Health, Education and Welfare publication (NIH) N.o 77-1247.
[17.]
H. Glick, J.F. Hayse, D. Thomson, R.S. Epstein, W.P. Stephenson, G. Oster.
A model for evaluating the cost-effectiveness of cholesterollowering treatment.
[18.]
W.B. Kannel, W.P. Castelli, T. Gordon, P.M. McNamara.
Serum cholesterol, lipoproteins, and the risk of coronary heart disease.
Ann Intern Med, 74 (1971), pp. 1-12
[19.]
M.A. Austin.
Plasma triglycerides and coronary heart disease.
Multiple risk factors and cardiovascular disease, pp. 229-233
Copyright © 2002. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.